Ep. 107 - A Tale of Two Targets: LAG3, IL-2; Plus Alternatives to Cash Up

BioCentury This Week

The importance of FDA’s approval of Bristol Myers' LAG3 inhibitor Opdualag nivolumab/relatlimab for melanoma, the pharma’s disruptive marketing strategy and what’s next among checkpoints in the clinic headline the latest BioCentury This Week podcast. BioCentury's editors also discuss why there’s still a lot of excitement regarding the IL-2 cancer pipeline despite last week’s setback for Nektar Therapeutics and the paths less traveled to raising money as the downturn grinds on. This week’s podcast is sponsored by life sciences investment firm Jeito Capital

Reach us by sending a text

2022-03-21 20 min 6 chapters

Available Results

Generated results are saved to the knowledge database for reuse and search.

No generated results are available for this episode yet.

Extract Knowledge

Pick what you want extracted first. Model, scope, and chapter options appear after a template is selected.

Generated results for public episodes are saved to the knowledge database so they can be reused and searched later.
No transcript is available for this episode yet.
Sign in to generate a transcript for review.
Sign in